Blood cancer therapy SGR-2921 discontinued after patient deaths
Biotech company Schrödinger said it’s discontinuing the development of SGR-2921, an experimental therapy for certain types of blood cancer, following the deaths of…
News
KRAS-mutated pancreatic cancer vaccine triggers immune response
A vaccine therapy called ELI-002 2P led to anti-cancer immune responses in a Phase 1 trial and showed potential for preventing disease relapses among people…
Patients needed for trial of CUE-102 for hard-to-treat glioblastoma
Enrollment is now open in a U.S. clinical trial testing the immune-modulating therapy CUE-102 in people with recurrent glioblastoma, an aggressive form of glioma…
Ovarian cancer patients wanted for Phase 3 trial of virus therapy
A Phase 3 clinical trial testing the experimental cancer-killing virus Olvi-Vec in people with hard-to-treat ovarian cancer is recruiting participants. Top-line results from the ongoing…
Sanofi multiple myeloma treatment gets FDA orphan drug status
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, an investigational therapy being developed by Sanofi for people with…
FDA fast tracks birelentinib for certain hard-to-treat blood cancers
The U.S. Food and Drug Administration (FDA) granted fast track designation to birelentinib as a potential treatment for certain forms of blood cancer. The…
Committee recommends study of pancreatic cancer vaccine continue
An independent committee has recommended that a clinical trial testing the experimental anticancer vaccine ELI-002 7P in people with pancreatic cancer should continue as…
Hemispherian gets FDA green-light for glioblastoma trial of GLIX1
The U.S. Food and Drug Administration (FDA) will allow Hemispherian to test its first-in-class experimental therapy for glioblastoma in a Phase 1 clinical trial.
2 of 3 ovarian cancer patients in study respond to SON-1010 combo
Sonnet Biotherapeutics is now testing its immunotherapy SON-1010, in combination with the immune checkpoint inhibitor Tecentriq (atezolizumab), in more patients — and soon, at…
Darzalex approved in EU to treat smoldering multiple myeloma
Johnson & Johnson‘s Darzalex (daratumumab) is now the first approved treatment for high-risk smoldering multiple myeloma (SMM) in the European Union (EU). SMM…
